Get the Stockscreener App
0.2798
0.00%
0.00
Relmada Therapeutics Inc Stock (RLMD) Forecast
The Relmada Therapeutics Inc (RLMD) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $7.1852, representing a +2,468% increase from the current price of $0.2798. The highest analyst price target is $11.13, and the lowest is $3.2408.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month RLMD Price Target
Average 6.4123
(+2,192% Upside)
Is Relmada Therapeutics Inc (RLMD) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 28.67 | Buy |
| STOCH(9,6) | 21.94 | Neutral |
| STOCHRSI(14) | 29.61 | Neutral |
| MACD(12,26) | -0.0608 | Buy |
| ADX(14) | 19.64 | Neutral |
| William %R | -93.14 | Buy |
| CCI(14) | -81.81 | Neutral |
Buy: 3
Sell: 0
Neutral: 4
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
0.3076
Sell
|
0.3022
Sell
|
| MA20 |
0.3225
Sell
|
0.3315
Sell
|
| MA50 |
0.3677
Sell
|
0.6518
Sell
|
| MA100 |
1.6617
Sell
|
1.3095
Sell
|
| MA200 |
2.4321
Sell
|
2.1214
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, RLMD could be considered a Strong Sell, with 17 technical analysis indicators signaling 3 Buy signals, 10 signaling Sell signals and 4 Neutral signals. This might not be a good time to consider opening new positions on RLMD, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 28.67 indicates that RLMD is oversold. This indicates that RLMD price has experienced a significant decline over a specified lookback period, potentially leading to a rebound.
- STOCH (Stochastic Oscillator): The STOCH value of 21.94 indicates that RLMD is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 29.61 indicates that RLMD is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 19.64 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -81.81 indicates that RLMD is still oversold but not to an extreme extent.
Long-term RLMD price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Relmada Therapeutics Inc financial reports and earnings history, Relmada Therapeutics Inc (RLMD) stock could reach $25.27 by 2030, $55.46 by 2040 and $40.16 by 2050. See the projected annual prices until 2050 of the Relmada Therapeutics Inc stock below:
- Relmada Therapeutics Inc (RLMD) is expected to reach an average price of $33.47 in 2035, with a high prediction of $36.17 and a low estimate of $33.39. This indicates an $11,861% rise from the last recorded price of $0.2798.
- Relmada Therapeutics Inc (RLMD) stock is projected to chart a bullish course in 2040, with an average price target of $56.24, representing an $19,999% surge from its current level. The forecast ranges from a conservative $31.53 to a sky-high $55.46.
- Our analysts predict Relmada Therapeutics Inc (RLMD) to jump 18,887% by 2045, soaring from $53.42 to an average price of $53.13, potentially reaching $55.54. While $53.42 is the low estimate, the potential upside is significant.
- Relmada Therapeutics Inc (RLMD) stock is expected to climb by 2050, reaching an average of $38.43, a $13,636% jump from its current level. However, a wide range of estimates exists, with high and low targets of $40.16 and $38.53, respectively, highlighting the market's uncertainty.
Relmada Therapeutics Inc Stock (RLMD) Year by Year Forecast
Relmada Therapeutics Inc Stock (RLMD) Price Forecast for 2025
Relmada Therapeutics Inc Stock (RLMD) is expected to reach an average price of $6.4123 in 2025, with a high prediction of $12.67 and a low estimate of $0.154. This indicates an +2,192% rise from the last recorded price of $0.2798.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| March, 2025 | $6.9141 | $3.2408 | $11.13 | +2,371% |
| April, 2025 | $10.79 | $5.3885 | $12.47 | +3,755% |
| May, 2025 | $4.314 | $1.8551 | $12.67 | +1,442% |
| June, 2025 | $8.1817 | $3.5184 | $8.4684 | +2,824% |
| July, 2025 | $2.5261 | $0.4894 | $9.4362 | +802.82% |
| August, 2025 | $0.4383 | $1.3928 | $0.8916 | +56.66% |
| September, 2025 | $1.9594 | $0.4838 | $5.3543 | +600.29% |
| October, 2025 | $0.2384 | $0.5173 | $3.6683 | -14.79% |
| November, 2025 | $4.2607 | $0.154 | $3.8955 | +1,423% |
| December, 2025 | $0.1685 | $3.6335 | $4.5418 | -39.78% |
Relmada Therapeutics Inc Stock (RLMD) Price Forecast for 2026
The predicted value for Relmada Therapeutics Inc (RLMD) in 2026 is set at an average of $11.29. Estimates vary from a peak of $22.45 to a trough of $0.1335, indicating an +3,935% surge from the present price of $0.2798.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $3.3107 | $1.3696 | $1.8807 | +1,083% |
| February, 2026 | $2.863 | $4.1419 | $3.0919 | +923.23% |
| March, 2026 | $0.2053 | $0.8647 | $0.6547 | -26.64% |
| April, 2026 | $9.2669 | $0.1908 | $9.4669 | +3,212% |
| May, 2026 | $5.5147 | $3.5147 | $10.95 | +1,871% |
| June, 2026 | $0.7624 | $0.508 | $6.6191 | +172.49% |
| July, 2026 | $1.2646 | $0.4054 | $1.6046 | +351.97% |
| August, 2026 | $4.5823 | $0.1335 | $4.7023 | +1,538% |
| September, 2026 | $11.83 | $4.0018 | $13.77 | +4,130% |
| October, 2026 | $15.25 | $10.86 | $16.78 | +5,351% |
| November, 2026 | $18.14 | $12.28 | $22.45 | +6,383% |
| December, 2026 | $9.0678 | $9.1822 | $18.91 | +3,141% |
Relmada Therapeutics Inc Stock (RLMD) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Relmada Therapeutics Inc (RLMD) is $8.1542, with a high forecast of $10.94 and a low forecast of $5.366. This indicates an +2,814% increase from the last price of $0.2798.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $10.24 | $9.5389 | $9.4501 | +3,560% |
| February, 2027 | $11.34 | $10.42 | $10.94 | +3,954% |
| March, 2027 | $9.5601 | $9.5801 | $10.61 | +3,317% |
| April, 2027 | $9.4724 | $9.4113 | $9.2357 | +3,285% |
| May, 2027 | $9.7146 | $9.4891 | $9.378 | +3,372% |
| June, 2027 | $9.2225 | $9.7225 | $9.7658 | +3,196% |
| July, 2027 | $8.4247 | $8.4547 | $8.8836 | +2,911% |
| August, 2027 | $8.027 | $8.2114 | $8.0053 | +2,769% |
| September, 2027 | $7.6948 | $7.7648 | $7.8025 | +2,650% |
| October, 2027 | $7.027 | $7.047 | $7.0704 | +2,411% |
| November, 2027 | $5.8493 | $6.3393 | $6.7926 | +1,991% |
| December, 2027 | $5.6471 | $5.366 | $5.3028 | +1,918% |
Relmada Therapeutics Inc Stock (RLMD) Price Forecast for 2028
In 2028, Relmada Therapeutics Inc (RLMD) is projected to reach an average price of $14.68, with a high projection of $29.28 and a low estimate of $0.0838. This indicates an +5,148% rise from the last price of $0.2798.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $4.8694 | $4.9494 | $5.0527 | +1,640% |
| February, 2028 | $4.4616 | $4.4816 | $4.5605 | +1,495% |
| March, 2028 | $4.1294 | $4.2294 | $4.284 | +1,376% |
| April, 2028 | $2.8317 | $3.2317 | $3.945 | +912.05% |
| May, 2028 | $0.8795 | $1.3895 | $2.4128 | +214.34% |
| June, 2028 | $1.1832 | $0.2006 | $1.4382 | +322.88% |
| July, 2028 | $0.456 | $0.2615 | $2.5496 | +62.96% |
| August, 2028 | $0.0981 | $0.0838 | $1.0893 | -64.92% |
| September, 2028 | $24.91 | $0.157 | $26.96 | +8,803% |
| October, 2028 | $30.25 | $26.68 | $26.40 | +10,710% |
| November, 2028 | $29.59 | $28.49 | $29.28 | +10,476% |
| December, 2028 | $27.40 | $27.87 | $27.88 | +9,691% |
Relmada Therapeutics Inc Stock (RLMD) Price Forecast for 2029
The 2029 price forecast for Relmada Therapeutics Inc Stock (RLMD) is $23.78 on average, with a high prediction of $29.07 and a low estimate of $18.49. This represents an +8,398% increase from the previous price of $0.2798.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $29.51 | $25.82 | $26.66 | +10,447% |
| February, 2029 | $24.91 | $29.87 | $29.07 | +8,801% |
| March, 2029 | $27.98 | $26.54 | $25.19 | +9,900% |
| April, 2029 | $24.20 | $27.65 | $27.22 | +8,551% |
| May, 2029 | $21.81 | $24.39 | $23.26 | +7,695% |
| June, 2029 | $20.54 | $23.51 | $22.91 | +7,239% |
| July, 2029 | $19.48 | $21.58 | $21.01 | +6,862% |
| August, 2029 | $18.45 | $18.49 | $17.87 | +6,492% |
| September, 2029 | $23.58 | $19.48 | $19.17 | +8,327% |
| October, 2029 | $19.76 | $20.34 | $21.03 | +6,961% |
| November, 2029 | $25.29 | $20.61 | $19.46 | +8,939% |
| December, 2029 | $26.02 | $27.72 | $26.45 | +9,201% |
Relmada Therapeutics Inc Stock (RLMD) Price Forecast for 2030
Relmada Therapeutics Inc Stock (RLMD) is expected to reach an average price of $20.31 in 2030, with a high forecast of $27.36 and a low forecast of $13.26. This signifies an +7,159% surge from the last price of $0.2798.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $19.77 | $22.21 | $25.27 | +6,966% |
| February, 2030 | $24.13 | $22.48 | $21.59 | +8,526% |
| March, 2030 | $23.90 | $23.65 | $22.85 | +8,441% |
| April, 2030 | $28.71 | $26.64 | $27.36 | +10,162% |
| May, 2030 | $23.39 | $23.52 | $24.84 | +8,259% |
| June, 2030 | $24.83 | $25.75 | $24.70 | +8,776% |
| July, 2030 | $21.37 | $21.80 | $24.35 | +7,537% |
| August, 2030 | $15.05 | $19.04 | $20.15 | +5,280% |
| September, 2030 | $13.70 | $13.26 | $13.31 | +4,796% |
| October, 2030 | $18.28 | $15.18 | $17.03 | +6,435% |
| November, 2030 | $19.31 | $19.39 | $17.94 | +6,801% |
| December, 2030 | $17.93 | $17.98 | $18.34 | +6,309% |
0.11%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):